|Bid||53.01 x 3000|
|Ask||54.42 x 3100|
|Day's Range||52.96 - 54.25|
|52 Week Range||46.94 - 70.05|
|Beta (3Y Monthly)||1.39|
|PE Ratio (TTM)||61.21|
|Earnings Date||Jan 24, 2019|
|Forward Dividend & Yield||1.64 (3.09%)|
|1y Target Est||59.75|
Following what the majority of brokers are saying about a particular stock can help understand its potential. Hence, when a broker upgrades a stock, one can easily rely on it.
Roche (RHHBY) signs collaboration agreement with Merck for developing a companion diagnostic test to identify patients for treatment with the latter's Keytruda.
Rising bond yields are creating new opportunities for income-seeking investors, but some companies are sweetening their payouts as well.
Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.
NEW YORK, NY / ACCESSWIRE / December 10, 2018 / U.S. stocks closed in the red on Friday as U.S. jobs report fell short of expectations and uncertainty over the U.S. -China trade talk spur markets lower. ...
Bristol-Myers Squibb Company and Vedanta Biosciences today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients with advanced or metastatic cancers.
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Bristol-Myers Squibb (BMY) closed the most recent trading day at $53.08, moving -0.32% from the previous trading session.
Chapel Hill-based Target PharmaSolutions is wrapping up 2018 with a pair of new partnerships, further pushing the fast-developing company toward what its CEO says will be a better 2019.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 6) Gritstone Oncology Inc (NASDAQ: GRTS ) Down In The Dumps ...
The Board of Directors of Bristol-Myers Squibb Company (BMY) today declared an increase of 2.5% percent in the company’s quarterly dividend, beginning in the first quarter of 2019. The dividend increase will result in a quarterly dividend of 41 cents ($0.41) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on February 1, 2019, to stockholders of record at the close of business on January 4, 2019.
The drug maker is down by a double-digit percentage so far this year, but BMO Capital Markets analyst Alex Arfaei lifted his rating to Outperform from Market Perform.
It is hard to say anything about McKesson that we have not said before — it is a high-quality business with extremely cheap shares. McKesson stock (MCK) is not just cheap — it’s incredibly cheap. McKesson, for example, benefited tremendously when billions of dollars worth of branded drugs lost their patents and went generic between 2009 and 2015.
The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung cancer.
Bristol-Myers Squibb Company will announce results for the fourth quarter of 2018 on Thursday, January 24, 2019. During a conference call at 10:30 a.m. ET on January 24, company executives will review financial information and will address inquiries from investors and analysts.
Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.
Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.